Related Experiment Videos
Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell
M Ozdemirli1, M El-Khatib, L C Foote
1Arthritis Center, Department of Pathology, Boston University School of Medicine, MA 02118, USA.
European Journal of Immunology
|February 1, 1996
Summary
Fas ligand (FasL) cytotoxicity negatively regulates T and B cell collaboration. Inhibiting FasL with Fas-Ig enhances immune cell proliferation, suggesting Fas-Ig as an immunopotentiating agent.
Area of Science:
- Immunology
- Cell Biology
Background:
- T/B cell collaboration is crucial for adaptive immunity.
- Fas ligand (FasL) mediated cytotoxicity plays a role in immune regulation.
Purpose of the Study:
- To investigate the impact of FasL cytotoxicity on T/B cell collaboration in vitro.
- To evaluate the role of different B cell activation pathways on FasL sensitivity.
- To assess the immunomodulatory potential of Fas-Ig as a FasL inhibitor.
Main Methods:
- In vitro co-culture of cloned T helper 1 cells and antigen-pulsed, activated B cells.
- Comparison of B cells activated via IgM, CD14, and CD40 receptors.
- Utilizing Fas-Ig fusion protein to block FasL-mediated cytotoxicity.
Main Results:
- T and B cell proliferation correlated with B cell resistance to FasL cytotoxicity.
- FasL inhibition using Fas-Ig significantly enhanced both T and B cell proliferation.
- Activated B cell populations exhibited varying sensitivity to FasL-mediated killing.
Conclusions:
- FasL cytotoxicity acts as a negative regulator of T and B cell proliferation.
- Fas-Ig demonstrates potential as an immunopotentiating agent for T and B cell immunity.
- Modulating FasL activity can influence adaptive immune responses.